Innate Pharma Management

Management criteria checks 4/4

Innate Pharma's CEO is Herve Brailly, appointed in Jan 1999, has a tenure of 25.25 years. directly owns 0.92% of the company’s shares, worth €1.66M. The average tenure of the management team and the board of directors is 4.1 years and 5.4 years respectively.

Key information

Herve Brailly

Chief executive officer

€100.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	25.3yrs
CEO ownership	0.9%
Management average tenure	4.1yrs
Board average tenure	5.4yrs

Recent management updates

Recent updates

CEO

Herve Brailly (62 yo)

25.3yrs

Tenure

€100,000

Compensation

Dr. Herve Brailly, Ph.D. Co-Founded Innate Pharma S.A in 1999 and served as its Chairman of Supervisory Board since December 31, 2016 until January 1, 2024 and serves as its Interim CEO and Chairman of the...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Herve Brailly	Co-Founder	25.3yrs	€100.00k	0.92% € 1.7m
Yannis Morel	Executive VP	8.9yrs	€599.92k	0.24% € 436.0k
François Romagné	Founder	no data	no data	no data
Eric Vivier	Founder	6.3yrs	no data	0.26% € 472.0k
Marc Bonneville	Founder	no data	no data	no data
Jean Fournié	Founder	no data	no data	no data
Alessandro Moretta	Founder	no data	no data	no data
Frederic Lombard	Senior VP & CFO	3yrs	no data	0.014% € 25.5k
Sonia Quaratino	Executive VP	less than a year	no data	no data
Arvind Sood	Executive VP	less than a year	no data	no data
Henry Wheeler	Vice President of Investor Relations & Communication	1.3yrs	no data	0.0039% € 7.2k
Odile Belzunce	Vice President of Compliance & Operations	5.3yrs	no data	0.077% € 139.7k

4.1yrs

Average Tenure

56yo

Average Age

Experienced Management: 0EVI's management team is considered experienced (4.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mario Sznol	Strategic Advisory Board Member	5.4yrs	no data	no data
Olivier Martinez	Member of Supervisory Board	no data	no data	no data
Ruslan Medzhitov	Strategic Advisory Board Member	5.4yrs	no data	no data
Gilles Brisson	Independent Member of Supervisory Board	16.8yrs	€29.00k	0.090% € 164.0k
Jean-Yves Blay	Independent Member of Supervisory Board	6.3yrs	€29.00k	0.000060% € 108.9
Irina Staatz-Granzer	Independent Chairwoman of Supervisory Board	14.8yrs	€42.00k	0.031% € 56.4k
Pascale Boissel	Independent Vice Chairperson of the Supervisory Board	3.9yrs	€60.00k	0.0012% € 2.3k
Miriam Merad	Chairman of Strategic Advisory Board	5.4yrs	no data	no data
Veronique Chabernaud	Independent Member of Supervisory Board	9yrs	€48.00k	0.00082% € 1.5k
Sebastian Amigorena	Strategic Advisory Board Member	5.4yrs	no data	no data
Aurelien Marabelle	Strategic Advisory Board Member	5.4yrs	no data	no data
Tanguy Seiwert	Strategic Advisory Board Member	5.4yrs	no data	no data

5.4yrs

Average Tenure

62yo

Average Age

Experienced Board: 0EVI's board of directors are considered experienced (5.4 years average tenure).

Innate Pharma Management

Management criteria checks 4/4

Key information

Recent management updates

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma S.A., Annual General Meeting, May 28, 2021

Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Recent updates

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Forecast to breakeven in 2026

Full year 2023 earnings released: €0.094 loss per share (vs €0.73 loss in FY 2022)

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

New minor risk - Share price stability

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

First half 2023 earnings released: EPS: €0.021 (vs €0.08 in 1H 2022)

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

No longer forecast to breakeven

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

First half 2022 earnings released: EPS: €0.08 (vs €0.30 loss in 1H 2021)

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

First half 2021 earnings released: €0.30 loss per share (vs €0.13 loss in 1H 2020)

Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides

Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting

Innate Pharma S.A. Announces New Lacutamab Data from Tellomak Trial in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma

Member of Supervisory Board Marcus Schindler has left the company

Full year 2020 earnings released: €0.81 loss per share (vs €0.31 loss in FY 2019)

Full year 2020 earnings released

Innate Pharma S.A. Advances Lacutamab Clinical Development Program

Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

Rosen Law Firm Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action

Innate Pharma S.A., Annual General Meeting, May 28, 2021

Innate Pharma Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients

New 90-day low: €3.10

New 90-day low - €3.70

First half earnings released

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age